Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (571-580 of 692) with videos related to

Pageof 70
Sort By:
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2015
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialEthan Basch, Allison M Deal, Mark G Kris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
The Prostate|September 1, 2020
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meetingAndrea K Miyahira, Kenneth J Pienta, John W Babich, et al.
Clinical Chemistry|February 24, 2009
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survivalPauliina Helo, Angel M Cronin, Daniel C Danila, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancerH I Scher, A J Armstrong, J D Schonhoft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Germline BRCA mutations denote a clinicopathologic subset of prostate cancerDavid J Gallagher, Mia M Gaudet, Prodipto Pal, et al.
European Urology Oncology|August 2, 2024
Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate CancerFourat Ridouani, H Alberto Vargas, Daniel J Holzwanger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate CancerKonrad H Stopsack, Subhiksha Nandakumar, Andreas G Wibmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Pageof 70

Showing results (571-580 of 692) with videos related to

Sort By:
Pageof 70
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2015
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialEthan Basch, Allison M Deal, Mark G Kris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2015
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelK N Chi, T Kheoh, C J Ryan, et al.
The Prostate|September 1, 2020
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meetingAndrea K Miyahira, Kenneth J Pienta, John W Babich, et al.
Clinical Chemistry|February 24, 2009
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survivalPauliina Helo, Angel M Cronin, Daniel C Danila, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancerH I Scher, A J Armstrong, J D Schonhoft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Germline BRCA mutations denote a clinicopathologic subset of prostate cancerDavid J Gallagher, Mia M Gaudet, Prodipto Pal, et al.
European Urology Oncology|August 2, 2024
Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate CancerFourat Ridouani, H Alberto Vargas, Daniel J Holzwanger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate CancerKonrad H Stopsack, Subhiksha Nandakumar, Andreas G Wibmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Pageof 70